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Abstract 1 
OBJECTIVE: To evaluate the chronicity of polypharmacy among older adults, and to 2 
identify factors associated with chronic polypharmacy. 3 
DESIGN: Longitudinal cohort study using register data.  4 
SETTING: Nationwide, Sweden.  5 
PARTICIPANTS: All 711,432 older adults (≥65 years) living in Sweden with 5 or more 6 
prescription drugs in October 2010 were included and followed-up until December 2013. 7 
Mean age at baseline was 77 (SD, 7.8) years, 59% were women, and 7% lived in nursing 8 
homes. 9 
MEASUREMENT: Monthly changes in the exposure to polypharmacy. Data regarding 10 
prescription drug use were extracted from the Swedish Prescribed Drugs Register.  11 
RESULTS:  Overall, 82% were continuously exposed to polypharmacy during ≥6 months, 12 
and 74% during ≥12 months. The proportion of individuals who remained exposed until the 13 
end of the study was 55%. Among the 21,361 individuals who had not been exposed to 14 
polypharmacy during the 6-month period before baseline (i.e. with a new episode of 15 
polypharmacy), only 30% remained exposed for ≥6 months. The proportion of older adults 16 
who spent at least 80% of their follow-up time with polypharmacy was substantially higher 17 
among prevalent polypharmacy users at baseline than among those with a new polypharmacy 18 
episode (80% vs 24%, p<0.01). Factors associated with chronic polypharmacy included 19 
higher age, female gender, living in an institution, chronic multimorbidity, and multi-dose 20 
dispensing. 21 
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CONCLUSION: Polypharmacy is most often chronic, although a substantial share of older 22 
adults experience short, recurring episodes of polypharmacy and are thus exposed to its 23 
potential harms in a transient rather than persistent manner.  24 
Keywords: duration; drugs; epidemiology; medication; polypharmacy25 
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Introduction 26 
Multimorbidity is common among older adults and often results in multiple medication use. 27 
Polypharmacy (commonly defined as the concurrent use of 5 or more drugs)1 is a concern 28 
because it has been linked to an array of negative health outcomes.2–6 The prevalence of 29 
polypharmacy has increased in most countries during the last decades 7–11. In the United 30 
States, it is estimated that about 40% of people aged 65 years or older use ≥5 drugs 31 
concomitantly.7 Yet few studies have documented the longitudinal development of 32 
polypharmacy over time, and little is known about the proportion of older adults who are 33 
chronically exposed to polypharmacy. Prior studies suggest that older adults tend to persist 34 
with polypharmacy over time.12–16 Factors such as higher age, female gender, high BMI, 35 
smoking and chronic conditions are associated with higher odds of remaining on 36 
polypharmacy.16 However, these studies were based on survey data with several years 37 
between each wave. The use of prescription drugs by older adults can fluctuate, and episodes 38 
of polypharmacy can occur sporadically. Newly diagnosed chronic conditions and temporary 39 
changes in health status (e.g. post-operative pain, infections) can for instance prompt an 40 
increase in the number of drugs, while deprescribing and lack of adherence can shorten the 41 
medication list. 42 
Understanding the chronicity of polypharmacy is important for a number of reasons17. First, 43 
most definitions of polypharmacy do not consider whether the exposure to polypharmacy is 44 
chronic or transient.18,19 Yet, this has implications for evaluating the quality of drug 45 
prescribing since short-term exposure to polypharmacy as a response to acute events is often 46 
clinically appropriate. Second, various interventions have been implemented to reduce the 47 
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prevalence and the harms of polypharmacy. Most of these interventions have proven 48 
unsuccessful.20,21 Potentially because polypharmacy may not always be a chronic and 49 
persistent hazard,22 making it difficult to provide tailored interventions at the right time for 50 
older adults18. Third, observational studies aiming at establishing a causal association 51 
between polypharmacy and subsequent health outcomes have seldom considered 52 
polypharmacy as a time-varying or cumulative exposure based on the assumption that 53 
polypharmacy is by definition chronic.23 Yet, until now, this assumption has remained 54 
untested and there exists no consensual definition of what constitutes chronic 55 
polypharmacy.19 Our aim was thus twofold: i) to evaluate the degree of chronicity of 56 
polypharmacy among older adults in Sweden, and ii) to identify factors associated with 57 
chronic rather than transient polypharmacy. 58 
59 
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Methods 60 
Study population 61 
We used register data with nationwide coverage in Sweden to create a longitudinal cohort of 62 
older adult (≥65 years) who were exposed to ≥5 drugs in October 2010. Study participants 63 
were followed prospectively until December 2013, i.e. for up to 37 months. The Swedish 64 
Prescribed Drug Register was linked to the National Patient Register, the National Cause of 65 
Death Register, and the Social Services Register, as described elsewhere.24 We excluded 66 
individuals who died during the first 12 months of follow-up, as people at the end of life 67 
might have specific clinical needs.25 The selection of the study population is presented in 68 
Supplementary materials Figure S1. 69 
Outcome measurement: polypharmacy 70 
Data regarding prescription drug use were extracted from the Swedish Prescribed Drugs 71 
Register, which collects information about all prescription drugs delivered in pharmacies in 72 
Sweden.26 Exposure periods were constructed for each dispensed drug based on: (i) the date 73 
of drug dispensing, (ii) the number of dispensed defined daily doses, and (iii) the prescribed 74 
daily dose as reported by the prescriber.27,28 We then calculated the number of different drugs 75 
used in each 30-day window, i.e. distinct substances according to the 5th level of Anatomical 76 
Therapeutic Chemical (ATC) classification system. As illustrated in Figure S2, individuals 77 
were considered as exposed to polypharmacy during a given month when the number of 78 
drugs was ≥5.  79 
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To distinguish “chronic” from “transient” polypharmacy exposure, we used the different 80 
approaches illustrated in Figure 1. Health problems are usually defined as “chronic” when 81 
they persist over time without any measurable interruptions (e.g. diabetes, heart failure). To 82 
reflect this, we calculated the duration of polypharmacy as the number of consecutive months 83 
spent with ≥5 different drugs. We considered the first episode, starting at baseline and 84 
stopping when the patient was no longer exposed to polypharmacy for at least 2 months. In 85 
other words, interruptions in polypharmacy exposure were discarded if they lasted ≤1 month. 86 
This ‘grace period’ was used to reduce the influence of irregular drug refill patterns. 87 
Chronicity of polypharmacy was calculated as the proportion of individuals who remained 88 
exposed for ≥6 months and ≥12 months.  89 
Other health problems do not persist over time without any measurable interruption, but can 90 
still be considered as chronic if people are experiencing them more often than not (e.g. 91 
chronic pain, psoriasis). The underlying assumption is that some conditions occur so 92 
frequently that their impact on people’s everyday life is constant although their onset appears 93 
as a series of discrete events. In order to mirror this second scenario, we calculated the 94 
fraction of time with polypharmacy by dividing the number of months with polypharmacy 95 
(numerator) by the total number of months of available follow-up (denominator). The 96 
numerator did include grace periods. We then defined chronic polypharmacy users as older 97 
adults who had a fraction of time with polypharmacy ≥80% (e.g. at least 30 months out of 37 98 
for those surviving the complete follow-up). This is similar to how drug adherence is 99 
calculated using the medication possession ratio.29 100 
[Figure 1 about here] 101 
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Other covariates 102 
Living arrangement at baseline was defined as ‘community-dwelling’ or ‘living in 103 
institution’, using data from the Social Services Register. Multimorbidity was assessed using 104 
a validated assessment tool (5), which captures 60 distinct chronic diseases using data from 105 
the national patient register during the 3 years prior to baseline, as well as data about specific 106 
medications dispensed during the same period. This variable was defined as the number of 107 
chronic conditions, with ≥5 conditions as the maximum value. Multi-dose dispensing (in 108 
Swedish, ApoDos) refers to drugs administered through portion packed plastic pouches. It is 109 
especially common among older adults living in nursing homes in Sweden.30 110 
Statistical analysis 111 
We calculated the duration of polypharmacy for each individual, and identified those who 112 
remained exposed for ≥ 6 and ≥12 consecutive months. To account for left censoring we 113 
stratified the population according to their exposure to polypharmacy during the 6-month 114 
period before baseline. Since we excluded older adults who died during the first year of 115 
follow-up, outcome measurement was not affected by right censoring (i.e. survival). 116 
However, the persistence of polypharmacy throughout the entire follow-up was analyzed 117 
with Kaplan-Meier survival functions accounting for mortality. We then measured the 118 
fraction of time with polypharmacy as the number of months spent with polypharmacy 119 
divided by the total number of months of available follow-up. The proportion of older adults 120 
who had a fraction of time with polypharmacy ≥80% was reported with percentages. Since 121 
this indicator is proportional to the contributing time of each individual, it is not affected by 122 
mortality selection. We analyzed factors associated with a high fraction of time with 123 
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polypharmacy using multivariate logistic regression models adjusted for age, sex, living 124 
arrangement, number of chronic conditions, dispensing regimen and number of drugs at 125 
baseline. All estimates from the logistic regression are calculated as predicted probabilities 126 
and presented as percentages (with 95% confidence intervals) using the margins command in 127 
Stata version 14.1 (StataCorp, College Station, TX). Predicted probabilities can be compared 128 
across models and can be interpreted as adjusted proportions conditional on the covariates.31 129 
Post hoc, we stratified the analysis by dispensing regimen to investigate the combined effect 130 
of living arrangement and dispensing regimen. In sensitivity analyses, the fraction of time 131 
with polypharmacy was categorized using a lower cut-off value (50% instead of 80%), which 132 
has previously been used as a definition of chronic polypharmacy 32 133 
Ethical approval 134 
Data were anonymized and the Regional Ethical Review Board in Stockholm approved the 135 
study (2013/1941-31/3 and 2015/1319-32). 136 
137 
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Results 138 
Out of 1,752,022 older adults (≥65 years) alive at baseline, 769,286 were exposed to 139 
polypharmacy. After excluding 57,854 individuals who died during the first 12 months of 140 
follow-up, the study population thus consisted of 711,432 older adults (Supplementary Figure 141 
S1). This represents 44% of the population aged ≥65 years in Sweden. Mean age at baseline 142 
was 77.4 years (SD 7.8), 59.1% were women. About 3% (n=21,361) of study participants 143 
started a new episode of polypharmacy, i.e. had not been exposed to polypharmacy during the 144 
6-month period before baseline (Table 1). Persons with a new episode of polypharmacy were 145 
on average younger, had fewer chronic conditions and used fewer drugs at baseline (Table 146 
S1). 147 
[Table 1] 148 
Polypharmacy was often long lasting. Overall, 82.3% of participants were exposed to 149 
polypharmacy for ≥6 months, and 74.3% for ≥12 months. Among older adults with a new 150 
polypharmacy episode, these proportions were 29.8%, and 18.6%, respectively (Table 2). The 151 
proportion of individuals who remained exposed to polypharmacy until the end of follow-up 152 
was 55.3% in the total study population, but only 9.3% among people who had not been 153 
exposed to polypharmacy before baseline. Among the 317,478 older adults who discontinued 154 
polypharmacy, 76.3% experienced at least one more episode of polypharmacy during the 155 
follow-up period (Table S2). As shown in Figure 2, polypharmacy persisted for a longer time 156 
among older adults aged 75 or older than among younger individuals. Episodes of 157 
polypharmacy were also longer among individuals with a higher number of medications at 158 
baseline (Figure S3).  159 
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[Table 2] 160 
[Figure 2] 161 
During follow-up, we observed 21.2 million person-months with polypharmacy out of a total 162 
of 25.3 million person-months of follow-up. The average fraction of time with polypharmacy 163 
was thus 84%, ranging from 80% among individuals aged 65–74 years to 89% among those 164 
aged 95 years and older. Table 3 shows the proportion of older adults with a high fraction of 165 
time with polypharmacy, i.e. exposed to polypharmacy for ≥ 80% of follow-up. In the total 166 
study population, 79.9% of older adults had a high fraction of time with polypharmacy, 167 
compared with 23.6% among persons with a new polypharmacy episode at baseline. After 168 
adjustment for potential confounders, this proportion increased with age, as well as with 169 
multi-dose drug dispensing compared with ordinary prescriptions (adjusted predicted 170 
probability 93% vs 78%, p<0.01). The proportion of nursing home residents with a high 171 
fraction of time with polypharmacy was higher than among community dwellers (90.7% vs 172 
79.1%). However, after adjustment for other covariates, this association was reversed 173 
(predicted probability 76.7% vs. 80.1%). In post-hoc analysis, we explored the interaction 174 
between living arrangement and drug dispensing scheme. This showed that community-175 
dwellers with multi-dose dispensing were in fact more likely to have a high fraction of time 176 
with polypharmacy than persons living in institution (Table S3). In sensitivity analyses where 177 
the fraction of time with polypharmacy was calculated without the one month grace period  178 
which yielded similar numbers, and using a cut-off value of ≥50% which left the association 179 
with other covariates largely unaffected although a larger proportion of older adults were 180 
classified as chronic polypharmacy users (Table S4 and S5). 181 
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Discussion 183 
This large longitudinal cohort study tracking monthly changes in drug utilization among 184 
older adults in Sweden shows that polypharmacy (concurrent use of ≥5 drugs) is often a 185 
chronic state. This was demonstrated with two complementary approaches. 186 
First, when focusing on the duration of polypharmacy episodes, our data clearly show that 187 
polypharmacy is persistent for a majority of older adults. About 75% of the individuals with 188 
polypharmacy at baseline remained exposed to polypharmacy for at least 12 consecutive 189 
months. Moreover, even though persons with a new polypharmacy episode at baseline were 190 
more likely to discontinue polypharmacy in the short term, more than three quarters of the 191 
people who stopped polypharmacy eventually transitioned back to polypharmacy before the 192 
end of the study period. This suggests that polypharmacy is often a chronic state, however a 193 
substantial share of older adults experience short episodes of polypharmacy and are thus 194 
exposed to its potential harms in a transient rather than persistent manner. This is especially 195 
true among those who are prescribed 3 to 4 medications for the management of chronic 196 
diseases (and who are likely to fluctuate around the threshold of 5 drugs used to define 197 
polypharmacy).  198 
Another way to assess the longitudinal exposure to polypharmacy is to investigate the 199 
proportion of months that older adults spend with polypharmacy. Contrary to duration, which 200 
measures the length of continuous and uninterrupted polypharmacy episodes and is therefore 201 
particularly sensitive to grace periods and right censoring (e.g. survival), the fraction of time 202 
with polypharmacy describes the burden of polypharmacy with respect to the available 203 
follow-up time. This approach is comparable to the methodology proposed by Franchi et al., 204 
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for defining chronic polypharmacy users, which consists in measuring the proportion of 205 
individuals exposed to polypharmacy at least 6 out of 12 months.32 In the present study, we 206 
found that 80% of older adults had a high fraction of time with polypharmacy (i.e. spent 207 
≥80% of follow-up with polypharmacy), which is indicative of a chronic exposure. Risk 208 
factors associated with high fraction of time with polypharmacy included higher age, female 209 
gender, living in institution, chronic multimorbidity, and multi-dose dispensing 33–35. When 210 
using the same cut-off value as Franchi et al.32 – namely being exposed to polypharmacy 211 
during more than 50% of the available months – 42% of older adults who started a new 212 
polypharmacy episode at baseline had chronic polypharmacy in our study. An unexpected 213 
finding was that the adjusted probability of spending a large proportion of months with 214 
polypharmacy was higher among people residing in the community than in nursing homes. 215 
However, more detailed analyses revealed that this association was mostly driven by multi-216 
dose dispensing – the small share of persons living in the community with multi-dose drug 217 
dispensing had the largest fraction of time with polypharmacy. The finding that people with 218 
multi-dose dispensing spend a higher fraction of time with polypharmacy is in agreement 219 
with previous Swedish studies showing that persons with multi-dose dispensing have fewer 220 
changes made to their drug regimens (e.g. dose adjustments, drug discontinuations and newly 221 
prescribed drugs) 3036. One suggested reason for the fewer changes is that prescribers have the 222 
possibility to renew all drugs at once, which is not possible with ordinary prescriptions 36. 223 
There currently exists no consensual definition of polypharmacy, but two aspects have been 224 
widely discussed: the number of drugs that defines polypharmacy in a clinically meaningful 225 
way,37,38 and the criteria that would allow for drawing the line between appropriate and 226 
inappropriate polypharmacy.20 These two dimensions – the intensity and the composition of 227 
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polypharmacy – are indeed important. However, only few studies have made a distinction 228 
between chronic and transient polypharmacy.19 Our study shows that exposure to 229 
polypharmacy is not always stable over time, and that transient polypharmacy episodes are 230 
not uncommon. The notion of temporality should thus be better accounted for in the future. 231 
Observational studies that have investigated the association between polypharmacy and 232 
negative health outcomes have seldom considered polypharmacy as a time-varying 233 
exposure.2,39 Yet, doing so would considerably improve the assessment of harms of 234 
polypharmacy and could potentially elucidate the question whether the effect of 235 
polypharmacy is cumulative (i.e. longer exposure to polypharmacy leads to an accumulated 236 
risk of adverse effects) or if polypharmacy is hazardous even if exposure is short-lasting. The 237 
potential cumulative hazard of polypharmacy was recently highlighted in a British study, 238 
which demonstrated that the associations between polypharmacy and physical and cognitive 239 
capabilities was more pronounced among older adults with a long-term exposure to 240 
polypharmacy.23  241 
Strengths and limitations 242 
The main strength of this study is that it includes the entire population of older adults aged 243 
≥65 years with polypharmacy in Sweden, followed up for 3 years. The monthly assessments 244 
of polypharmacy exposure provides better time resolution of the fluctuations in 245 
polypharmacy status than earlier survey-based studies with longer time periods between 246 
survey waves.12–16,23 There are some notable limitations to the study. First, we assessed 247 
monthly exposure to polypharmacy rather than weekly or even daily exposure periods, which 248 
could overlook some of the fluctuations in drug use. The choice of monthly time windows 249 
was dictated by the considerable computation power required to calculate concurrent drug 250 
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exposure for a population of 700,000 individuals over 3 years with a more detailed time 251 
resolution. It should also be noted that drugs used in hospitals are not recorded in the Swedish 252 
Prescribed Drug Register, and a one-month stay in hospital could thus result in a change in 253 
polypharmacy because of not filling new prescriptions. Additionally, over the counter drugs 254 
are not recorded in the Swedish Prescribed Drug Register, this most likely leads to an 255 
underestimation of the individual burden of polypharmacy. Adherence to different 256 
medications could lead to misclassification of the exposure to polypharmacy in this study: 257 
our data do not provide information about drugs that were prescribed but never dispensed or 258 
whether the dispensed drugs were actually consumed. Our results should be interpreted in the 259 
light of this limitation. To reduce the risk of overestimating short-term fluctuations, we only 260 
considered polypharmacy to be discontinued if two consecutive months were spent without 261 
polypharmacy. Second, we calculated the number of drugs by summing together all distinct 262 
ATC codes including medications intended for short-term use that do not contribute to 263 
chronic polypharmacy. However, considering all prescribed drugs reflects the natural course 264 
of polypharmacy in the older population. Fourth, we tried to isolate people with a new 265 
episode of polypharmacy at baseline from those who had already been exposed. This is 266 
because incident polypharmacy users have been proposed as a promising target for future 267 
interventions.23 However, because we could only construct a 6-month washout period before 268 
baseline, we cannot be certain that these individuals have a truly incident episode of 269 
polypharmacy. Last, polypharmacy is often a result of multimorbidity. We were able to 270 
account for the number of chronic conditions at baseline. However, future studies should also 271 
investigate how severity of different conditions affects chronicity of polypharmacy.  272 
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In conclusion, in this longitudinal study of more than half a million older people followed for 273 
up to three years, we found that that about 75% of the persons with polypharmacy were 274 
exposed to polypharmacy for at least 12 consecutive months. A large majority of older adult 275 
was also exposed to polypharmacy for more than 80% of the total study months. Our results 276 
therefore suggest that polypharmacy is most often chronic, but that a substantial share of 277 
older adults experience short, recurring episodes of polypharmacy and are thus exposed to its 278 
potential harms in a transient rather than persistent manner. This highlights the need to 279 
consider polypharmacy as a dynamic state in both epidemiological studies and in clinical 280 
practice. 281 
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Figure captions 313 
Figure 1. Fictitious example of two persons followed from baseline until the end of the study 314 
period, i.e. for a follow-up time of 37 months in total.  Each square represents 1 month.  The 315 
washout period of 6 months before baseline is used to distinguish persons who were already 316 
exposed to polypharmacy before baseline (Person A) from those who started a new 317 
polypharmacy episode at baseline (Person B). Each episode of polypharmacy starts at the 318 
first month of exposure, and ends when the person remains unexposed for at least 2 319 
consecutive months (grace period). In this example, both persons are considered as having a 320 
first episode of polypharmacy that persisted for 7 months, followed by 2 other episodes of 321 
polypharmacy. The fraction of time with polypharmacy is calculated as the number of 322 
months with polypharmacy – including grace periods – divided by the total number of 323 
months of available follow-up. In this example, the fraction of time with polypharmacy is 324 
equal to 33÷37 (89.2%). Thus, considering a cut-off value of ≥80%, these persons are defined 325 
as chronic polypharmacy users. 326 
 327 
Figure 2: Kaplan-Meier survival functions. Solid-line curves denotes the persistence of 328 
polypharmacy with a 2-month grace period. Dotted-line curves denotes the persistence of 329 
polypharmacy with no grace period (sensitivity analysis). Vertical dashed lines indicate 330 
polypharmacy exposure at 6 and 12 months, respectively. 331 
332 
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Table 1. Characteristics of older adults with polypharmacy at baseline (Sweden, 2010) 313 
Sex, No (%)  
   Men 291,175 (40.9%) 
   Women 420,257 (59.1%) 
Age  
Mean (SD) 77.4 (7.8) 
No (%)  
   65-74 years 300,810 (42.3%) 
   75-84 years 273,069 (38.4%) 
   85-94 years 129,715 (18.2%) 
   95 years + 7,838 (1.1%) 
Living arrangement, No (%)  
   Community 658,693 (92.6%) 
   Institution 52,739 (7.4%) 
Number of chronic conditions  
Mean (SD) 3.7 (2.6) 
No (%)  
0 41,256 (5.8%) 
1 102,904 (14.5%) 
2 122,735 (17.2%) 
3 116,609 (16.4%) 
4 98,338 (13.8%) 
≥5 229,590 (32.3%) 
Drug dispensing scheme, No (%)  
   Ordinary prescription 611,123 (85.9%) 
   Multi-dose dispensing 100,309 (14.1%) 
Number of drugs at baseline  
Mean (SD) 8.0 (3.1) 
No (%)  
5 149,247 (21.0%) 
6 128,527 (18.1%) 
7 105,530  (14.8%) 
8 83,972 (11.8%) 
9 65,710 (9.2%)  
≥10 178,446 (25.1%) 
Polypharmacy during the 6-month 
period before baseline, No (%) 
 
No 21,361 (3.0%) 
Yes 690,071 (97.0%) 
Death during follow-up, No (%)  
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   Between 12 and 24 months 54,476 (7.7%) 
   Between 25 and 37 months 57,027 (8.0%) 
Survived follow-up 599,792 (84.3%) 
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Table 2. Persistence of polypharmacy (≥5 drugs) among older adults in Sweden.  
 
Entire cohort 
(n=711,432 ) 
 Older adults with a new 
polypharmacy episode at baseline 
(n=21,361) 
≥ 6 months ≥12 months  ≥ 6 months ≥12 months 
% %  % % 
Total 82.3 74.3  29.8 18.6 
Sex      
   Men 81.8 73.2  31.9 19.9 
   Women 82.7 75.0  28.2 17.6 
Age      
   65-74 years 78.1 68.5  26.8 15.6 
   75-84 years 84.2 76.7  33.0 21.6 
   85-94 years 87.8 82.0  36.5 25.6 
   95 years + 88.6 83.2  29.5 17.0 
Living arrangement      
   Community 81.4 73.0  29.4 18.1 
   Institution 93.7 90.5  48.4 37.9 
Number of chronic conditions      
0 65.2 53.3  20.5 11.5 
1 73.2 62.4  25.2 14.7 
2 77.4 67.7  29.9 18.2 
3 81.2 72.2  34.0 21.7 
4 84.8 77.0  36.3 24.2 
≥5 91.7 86.7  44.1 31.5 
Drug dispensing scheme      
   Ordinary prescription 80.2 71.2  29.1 17.8 
   Multi-dose dispensing 95.5 93.0  51.4 41.8 
Number of drugs at baseline      
5 55.0 41.8  23.4 13.7 
6 76.1 64.3  35.1 21.5 
7 86.7 77.7  46.5 31.2 
8 92.0 85.4  56.2 40.3 
9 95.0 90.2  69.1 56.6 
≥10 97.8 95.5  78.4 67.3 
Death during follow-up      
   Between 12 and 24 months 90.5 85.9  43.8 34.6 
   Between 25 and 37 months 89.4 84.4  41.6 29.8 
Survived follow-up 80.9 72.3  28.6 17.4 
a Duration of polypharmacy was calculated as the number of consecutive months with polypharmacy, with a 2-
month grace period (see methods for more information) .
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Table 3. Proportion of older adults with a high fraction of time with polypharmacy (≥80%) 
during follow-up 
 Entire cohort 
(n=711,432 ) 
Older adults with a new 
polypharmacy episode at baseline 
(n=21,361  
Crude % Adjusted 
%a 
95% CI Crude % Adjusted %a 95% CI 
Total 79.9 79.9 (79.8-80.0) 23.6 23.6 (23.1-24.2) 
Sex       
   Men 79.3 80.5 (80.4-80.6) 24.5 24.4 (23.6-25.2) 
   Women 80.0 79.5 (79.4-79.6) 22.9 23.0 (22.3-23.7) 
Age       
   65-74 years 74.8 77.7 (77.6-77.8) 19.5 20.5 (19.8-21.2) 
   75-84 years 82.5 81.6 (81.5-81.7) 27.8 27.1 (26.1-28.1) 
   85-94 years 86.1 82.7 (82.5-82.9) 33.2 29.4 (27.5-31.2) 
   95 years + 85.9 81.1 (80.2-82.0) 31.0 22.3 (15.7-28.8) 
Living arrangement       
   Community 79.1 80.1 (80.0-80.2) 23.1 23.4 (22.9-24.0) 
   Institution 90.7 76.7 (76.1-77.3) 47.2 29.4 (25.1-33.7) 
Number of chronic conditions       
0 60.6 75.5 (75.2-75.8) 15.3 17.4 (16.1-18.7) 
1 69.5 78.0 (77.8-78.2) 18.7 20.1 (19.0-21.1) 
2 74.4 78.7 (78.5-78.9) 23.8 24.1 (22.9-25.2) 
3 78.5 79.6 (79.4-79.8) 27.1 26.0 (24.6-27.4) 
4 82.8 81.1 (80.9-81.4) 30.8 28.5 (26.6-30.4) 
≥5 90.5 84.1 (83.9-84.3) 37.5 31.8 (29.8-33.8) 
Drug dispensing scheme       
   Ordinary prescription 77.8 79.1 (79.0-79.2) 22.7 23.0 (22.4-23.6) 
   Multi-dose 92.8 87.9 (87.6-88.2) 50.6 39.9 (35.7-44.1) 
Number of drugs at baseline       
5 51.6 55.8 (55.6-56.1) 19.1 19.5 (18.9-20.2) 
6 72.1 74.1 (73.8-74.3) 26.7 26.4 (25.1-27.6) 
7 83.7 84.2 (84.0-84.4) 35.2 34.2 (32.0-36.5) 
8 90.1 89.8 (89.6-90.0) 41.2 38.0 (34.4-41.6) 
9 93.8 93.3 (93.1-93.5) 61.4 55.3 (49.6-61.0) 
≥10 97.2 96.6 (96.5-96.7) 63.3 56.5 (49.4-63.5) 
a Probabilities mutually adjusted for the other covariates in the table. 
 
